Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
Executive Summary
With positive data now in for Xarelto’s ability to treat and prevention recurrence of VTE, Janssen looks to file for a fourth indication for the novel anticoagulant, positioning the drug to crack a promising market that may be under-appreciated.